Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
58.81
+1.47 (+2.56%)
Official Closing Price
Updated: 7:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
29,064,455
Open
59.47
Bid (Size)
59.08 (900)
Ask (Size)
59.10 (600)
Prev. Close
57.34
Today's Range
58.78 - 60.64
52wk Range
43.08 - 93.80
Shares Outstanding
N/A
Dividend Yield
1.99%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
January 09, 2026
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...
Via
MarketMinute
The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance
January 09, 2026
As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...
Via
MarketMinute
Topics
Economy
Performance
YTD
+12.3%
+12.3%
1 Month
+19.9%
+19.9%
3 Month
+3.3%
+3.3%
6 Month
-14.7%
-14.7%
1 Year
-31.8%
-31.8%
More News
Read More
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
January 09, 2026
Via
PredictStreet
Topics
Earnings
Economy
Intellectual Property
Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
January 08, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
3 of the Best Stocks Under $100 to Buy in 2026
↗
January 08, 2026
Via
The Motley Fool
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
January 07, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’
↗
January 05, 2026
Via
Stocktwits
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
January 07, 2026
Via
MarketMinute
Topics
Economy
Warning: This Skyrocketing Stock Has a Hidden Risk
↗
January 06, 2026
Via
The Motley Fool
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?
↗
January 06, 2026
Via
The Motley Fool
Topics
Intellectual Property
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
January 06, 2026
Via
MarketMinute
Topics
Economy
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
January 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
January 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?
↗
January 06, 2026
Via
The Motley Fool
Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown?
↗
January 06, 2026
Via
Stocktwits
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List
↗
January 05, 2026
Via
Stocktwits
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms
↗
January 05, 2026
Via
Stocktwits
Is It Time to Dump Your Shares of Eli Lilly?
↗
January 05, 2026
Via
The Motley Fool
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026
↗
January 03, 2026
Via
The Motley Fool
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
January 02, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
World Trade
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
January 02, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
January 01, 2026
Via
MarketMinute
Topics
Intellectual Property
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
January 01, 2026
Via
PredictStreet
Topics
Economy
Lawsuit
World Trade
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
December 31, 2025
Via
MarketMinute
Topics
Economy
Intellectual Property
Law Enforcement
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026
↗
December 31, 2025
Via
MarketBeat
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 58.81
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 01/09/26 07:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.